Cosmos Health FY2022 revenue down 10.5% to $50.3M; positive adjusted EBITDA, debt reduced 76%

Cosmos Health Inc.

2023-Q1 EPS reported -$0.04 revenue$12,349,777

Revenue $50.3M vs $56.2M; constant-currency increase of $0.4M; net loss $13.8M vs $7.96M.
Adjusted EBITDA positive $0.5M (down from $3.3M in FY2021); going-concern doubt resolved.
Cash & securities $21M (vs $0.3M); long-term debt cut to $5.1M from $21.4M.
Raised $56.5M via equity/warrants; acquiring Cana Laboratories and ZipDoctor.
R&D partnership with Cloudpharm for obesity/diabetes; launched Mediterranation supplements.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cosmos Health Inc. reported fiscal year ended December 31, 2022 results: revenue $50.3 million, net income $(13,830,371).

Period: fiscal year ended December 31, 2022
Revenue: $50.3 million
Net income: $(13,830,371)
Result: reported results

Exact text from the filing

devices, today provided a business update and reported financial results for the fiscal year ended December 31, 2022. Fiscal Year 2022 Financial Highlights · Revenues were $50.3 million versus $56.2 million in FY2021 with the decline being largely due to the high variation in FX differences between EUR and GBP to USD. When considered on a constant currency

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cosmos Health Inc. filing history →

Source: SEC EDGAR

accession 0001477932-23-002688

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.